The mechanism underlying the efficacy of dupilumab in DEB is unknown, but blocking IL-4Ra-mediated sensitization of sensory neurons to various pruritogens has been proposed. 5 To the best of our knowledge, this is the first report of dupilumab in the treatment of pruritus in a DEB patient under 3 years old.This case supports that dupilumab may be considered an effective and safe treatment option for pruritus in these patients.